Avril Daly

Our Retina International World Congress (RIWC24) takes place from the 5th – 8th June 2024 in the Dublin Royal Convention Centre, in the heart of Dublin city centre.

Our Scientific Committee has been working relentlessly to secure an impressive lineup of outstanding speakers to shed light on this research area so as part of our Meet the Speaker series, we are delighted to announce one more distinguished speaker.

Avril Daly is CEO of the patient-led global umbrella organisation, Retina International, which represents the voice of charities and foundations concerned with the promotion of retina research and related health policy in 43 countries.

We are delighted to have Avril Daly with us at the Retina International World Congress as a panellist at the ‘High unmet medical needs in retinal degenerations.’ panel on Friday, June 7, 4:45 PM – 5:45 PM.

Image description: Headshot of Avril Daly on a blue background image. Text: Retina International World Congress. Dublin Royal Convention Centre, Dublin, Ireland. RIWC24. DUBLIN: Targeting the Cure. JUNE 5-8, 2024. AVRIL DALY, CEO, Retina International. At the bottom of the image, there are the Fighting Blindness and Retina International logos.

Avril has worked in health policy for rare and common eye disease since 2000 and was CEO of the Irish NGO, Fighting Blindness for eight years. She was Chairperson of Rare Disease Ireland from 2006-2019. In 2009 she was elected to the Board of Directors of Rare Disease Europe – EURORDIS, and is now the President of the organisation.

In 2011 Avril was appointed by the Irish Minister for Health to a steering committee working towards the development of the Irish National Plan for Rare Diseases. The plan was published in 2014. She was appointed to the Irish Clinical Programme for Rare Diseases at the Health Service Executive (HSE) in Ireland in 2014 and was recently appointed to the Rare Disease Technology Review Committee and the National Centre of Pharmacoeconomics (NCPE) to review orphan therapies that fail initial Health Technologies Assessment (HTA) for statutory reimbursement.

Avril has held board positions with the European Patient Forum, The European Platform for Patient Organisation Science and Industry (EPPOSI), the HRCI (formerly Medical Research Charities Group) in Ireland and IPPOSI, the Irish Platform for Patients Organisation Science and industry. She believes that patients have a critical role to play in aiding the development of appropriate interventions from concept to delivery.

Avril holds a Bachelors Degree in Business and International relations, she is affected by Retinitis Pigmentosa.

Stay tuned for more updates as we draw closer to this incredible gathering of the latest scientific research and innovation, set to take place in June 2024!

To learn more about Retina International please click here.